

Epigenetic Toxicology in Developmental Origins of Health and Disease

Pewee Papyri*

Department of Regulatory and Forensic Toxicology, Institute of Medical Expertise in Lodz, Poland

Abstract

Epigenetic toxicology plays a crucial role in understanding how environmental exposures during critical developmental periods influence long-term health outcomes. The Developmental Origins of Health and Disease (DOHaD) hypothesis suggests that early-life environmental factors, including exposure to toxicants, can induce persistent epigenetic modifications, such as DNA methylation, histone modifications, and non-coding RNA regulation. These alterations can dysregulate gene expression, predisposing individuals to chronic diseases such as metabolic disorders, cardiovascular diseases, neurodevelopmental impairments, and cancers later in life. Common environmental toxicants, including endocrine-disrupting chemicals (EDCs), heavy metals, air pollutants, and persistent organic pollutants (POPs), have been linked to epigenetic changes that impact fetal programming and disease susceptibility. Understanding the mechanisms by which toxicant-induced epigenetic alterations contribute to disease risk is essential for developing early biomarkers of exposure, preventive strategies, and targeted interventions. This review explores the latest advancements in epigenetic toxicology within the DOHaD framework, highlighting key toxicants, mechanisms, health implications, and future research directions.

Keywords: Epigenetic toxicology; Developmental Origins of Health and Disease; DOHaD; DNA methylation; Histone modification

Introduction

The Developmental Origins of Health and Disease (DOHaD) hypothesis posits that environmental exposures during critical windows of development can have lasting effects on health and disease susceptibility. Epigenetic toxicology, which examines how environmental toxicants influence gene regulation through epigenetic modifications, is central to understanding these long-term health impacts [1]. Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA regulation, do not alter the genetic code but can lead to persistent changes in gene expression patterns. These changes can influence physiological development, metabolic function, and disease risk across the lifespan and even in subsequent generations. A growing body of research links prenatal and early-life exposure to environmental contaminants such as endocrine-disrupting chemicals (EDCs), heavy metals, air pollutants, and persistent organic pollutants (POPs) to adverse epigenetic modifications [2]. These toxicants can interfere with normal fetal programming, leading to an increased risk of cardiovascular diseases, metabolic disorders, neurodevelopmental impairments, and cancers later in life. For example, exposure to bisphenol A (BPA), phthalates, arsenic, and polycyclic aromatic hydrocarbons (PAHs) has been shown to induce DNA methylation changes in key regulatory genes associated with these conditions. The transgenerational effects of toxicant-induced epigenetic modifications are also a growing concern. Studies suggest that environmental exposures can alter germline epigenetic marks, leading to disease susceptibility in offspring and subsequent generations, even in the absence of continued exposure. This raises significant implications for public health, emphasizing the need for preventive strategies and regulatory interventions to mitigate environmental risks during pregnancy and early development [3].

Despite increasing evidence of the role of epigenetic toxicology in DOHaD, many questions remain regarding the mechanistic pathways, dose-response relationships, and individual susceptibility factors that determine long-term health outcomes. Addressing these knowledge gaps requires interdisciplinary research integrating epigenetics, toxicology, developmental biology, and public health. This review explores the latest findings on epigenetic toxicology within the DOHaD

framework, highlighting key toxicants, molecular mechanisms, health implications, and future research directions [4].

Discussion

The interplay between epigenetic toxicology and the Developmental Origins of Health and Disease (DOHaD) hypothesis underscores the long-term consequences of early-life environmental exposures. Toxicants such as endocrine-disrupting chemicals (EDCs), heavy metals, air pollutants, and persistent organic pollutants (POPs) have been shown to induce epigenetic modifications that contribute to disease susceptibility later in life. This section explores the key findings in this field, including mechanisms of toxicity, transgenerational effects, and public health implications [5].

Mechanisms of Epigenetic Toxicity

Environmental toxicants influence epigenetic regulation through several key mechanisms:

DNA Methylation: Exposure to heavy metals (e.g., arsenic, cadmium, lead) has been linked to altered DNA methylation patterns, leading to the silencing or activation of genes involved in metabolism, immune function, and neurodevelopment.

Histone Modifications: Chemicals such as bisphenol A (BPA) and phthalates can modify histone acetylation and methylation patterns, impacting chromatin structure and gene expression in ways that predispose individuals to obesity, diabetes, and cancer [6].

***Corresponding author:** Pewee Papyri, Department of Regulatory and Forensic Toxicology, Institute of Medical Expertise in Lodz, Poland, E-mail: peweepapyri@gmail.com

Received: 01-Jan-2025, Manuscript No: wjpt-25-163623, **Editor Assigned:** 03-Jan-2025, pre QC No: wjpt-25-163623 (PQ), **Reviewed:** 17-Jan-2025, QC No: wjpt-25-163623, **Revised:** 24-Jan-2025, Manuscript No: wjpt-25-163623 (R), **Published:** 30-Jan-2025, DOI: 10.4172/wjpt.1000289

Citation: Pewee P (2025) Epigenetic Toxicology in Developmental Origins of Health and Disease. World J Pharmacol Toxicol 8: 289.

Copyright: © 2025 Pewee P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Non-Coding RNA Regulation: MicroRNAs (miRNAs) play a critical role in post-transcriptional gene regulation. Studies suggest that airborne pollutants (e.g., particulate matter, polycyclic aromatic hydrocarbons) can dysregulate miRNA expression, contributing to inflammatory responses, oxidative stress, and cardiovascular disease.

The persistence of these modifications highlights the potential for long-term and even transgenerational effects, as epigenetic marks can be inherited by offspring without direct toxicant exposure [7].

Transgenerational Epigenetic Effects

Emerging research indicates that epigenetic alterations induced by toxicants may be passed down to subsequent generations, amplifying health risks over time. Animal studies have demonstrated that prenatal exposure to pesticides, EDCs, and heavy metals can lead to metabolic disorders, reproductive dysfunction, and neurodevelopmental abnormalities in offspring for multiple generations. These findings raise concerns about heritable disease risk and underscore the need for stringent regulations to limit exposure to known epigenetic disruptors [8].

Implications for Public Health and Disease Prevention

The role of epigenetic toxicology in DOHaD has significant public health implications, particularly for vulnerable populations. **Early-Life Exposure Monitoring:** Biomarkers of epigenetic modifications could serve as early indicators of toxicant exposure, allowing for targeted interventions before disease onset [9].

Regulatory Policies and Risk Assessment: Stronger regulations on industrial chemicals, air pollution, and food contaminants are needed to reduce epigenetic toxicant exposure during critical developmental windows.

Personalized Medicine Approaches: Understanding individual susceptibility to epigenetic changes may lead to personalized prevention strategies, particularly for diseases with strong environmental and epigenetic components [10].

Conclusion

Epigenetic toxicology provides a crucial framework for understanding how environmental exposures during early life contribute to long-term disease risk. While significant progress has been made in identifying toxicant-induced epigenetic modifications, many challenges remain, including the need for standardized biomarkers, long-term human studies, and regulatory action. Future research should focus on elucidating molecular pathways, assessing transgenerational risks, and developing targeted intervention strategies to mitigate the effects of environmental toxicants on human health. A multidisciplinary approach combining epigenetics, toxicology, developmental biology, and epidemiology will be essential in addressing these challenges and advancing public health protection.

References

1. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, et al. (2012) Disease characterization using LQTS-specific induced pluripotent stem cells. *Cardiovasc Res* 95: 419-429.
2. Engler AJ, Carag-Krieger C, Johnson CP, Raab M, Tang HY, et al. (2008) Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: Scar-like rigidity inhibits beating. *J Cell Sci* 121: 3794-3802.
3. Anderson D, Self T, Mellor IR, Goh G, Hill SJ, et al. (2007) Transgenic enrichment of cardiomyocytes from human embryonic stem cells. *Mol Ther* 15: 2027-2036.
4. Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, et al. (2013) Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. *EMBO J* 32: 3161-3175.
5. Akala EO (2004) Oral controlled release solid dosage forms. *Theory Pract Contemp Pharm* CRC Press Florida: pp 333-366.
6. Malm CJ, Emerson J, Hiait GD (1951) Cellulose acetate phthalate as an enteric coating material. *J Am Pharm Assoc (Scientific Ed.)* 40: 520-525.
7. Hillery A, Park K (2016) *Drug Delivery: Fundamentals and Applications*. CRC Press.
8. Yun Y, Lee BK, Park K (2014) Controlled drug delivery systems: the next 30 years. *Front Chem Sci Eng* 8: 276-279.
9. Vargason AM, Anselmo AC, Mitragotri S (2021) The evolution of commercial drug delivery technologies. *Nat Biomed Eng* 5: 951-967.
10. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ (2021) Advances in oral drug delivery. *Front Pharmacol* 12.